Ziopharm Presents Positive Phase II Data for ZIO-201

Ziopharm Oncology reported data from a Phase II study of ZIO-201, which is used in soft tissue and bone sarcomas.

The study includes 54 patients. Of 44 evaluable patients, 48 percent had stable disease or better with a median progression-free survival of 10 weeks, Ziopharm said.

Of the 11 patients enrolled in the study who had not previously received the chemotherapy agent ifosfamide, stable disease or better was reported in 64 percent of patients and the median progression-free survival has not yet been reached.

The most common toxicities were mild to moderate and gastrointestinal or renal related.

Data from the study will support plans for the development and initiation of a randomized Phase III study of ZIO-201 in 2008.